|
|
Interleukin-2 |
|
Vaxjo ID |
56 |
|
Vaccine Adjuvant Name |
Interleukin-2 |
|
Adjuvant VO ID |
VO_0001298
|
|
Stage of Development |
Clinical Trial |
|
Components |
Native human IL-2 contains 133 amino acids; aldesleukin contains 132 amino acids. IL-2 exists as six alpha helical domains, termed A to F. Glycosylation not essential for function (Vogel and Powell, 1995). |
|
Preparation |
The primary adjuvant is co-emulsified with antigens and lipids, with polyethylene glycol modified long acting form (PEG IL-2), or liposome encapsulated sustained release dosage form (Vogel and Powell, 1995). |
|
Dosage |
Low doses may give up to 25-fold increase in adjuvant effect, with inhibition of adjuvant effect at high doses. May induce cellular immunity when given systemically, and IgA when administered at a mucosal surface (Vogel and Powell, 1995). |
|
Function |
IL-2 supports the growth and proliferation of antigen-activated T lymphocytes and plays a central role in the cascade of cellular events involved in the immune response. Proliferating T-cells also produce a variety of other lymphokines which may modulate other arms of the immune system. In view of these direct and indirect actions of IL-2 on the immune response, IL-2 may function as an adjuvant to vaccination by increasing the specific and durable response to vaccine immunogens (Vogel and Powell, 1995). |
|
Safety |
As a primary adjuvant, co-emulsified with antigens and lipids, with polyethylene glycol modified long acting form (PEG IL-2), or liposome encapsulated sustained release dosage form.changes. Further descriptions are indicated in the Proleukin& (Aldesleukin for Injection) package insert (Chiron Corporation, Emeryville, CA, U.S.A.) (Vogel and Powell, 1995). |
| Related Vaccine(s) |
|
| References |
Vogel and Powell, 1995: Vogel FR, Powell MF. A compendium of vaccine adjuvants and excipients. Pharmaceutical biotechnology. 1995; 6; 141-228. [PubMed: 7551218].
|
|
